A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
Brett G.M. Hughes, Alexander Guminski, Samantha Bowyer, Michael R. Migden, Chrysalyne D. Schmults, Nikhil I. Khushalani, Anne Lynn S. Chang, Jean Jacques Grob, Karl D. Lewis, George Ansstas, Fiona Day, Rahul Ladwa, Brian N. Stein, Eva Muñoz Couselo, Friedegund Meier, Axel Hauschild, Dirk Schadendorf, Nicole Basset-Seguin, Badri Modi, Sophie Dalac-RatLara A. Dunn, Lukas Flatz, Laurent Mortier, Sarah Guégan, Lucie M. Heinzerling, Janice M. Mehnert, Sabiha Trabelsi, Ainara Soria-Rivas, Alexander J. Stratigos, Claas Ulrich, Deborah J. Wong, Marie Beylot-Barry, Paolo Bossi, Cristina Bugés Sánchez, Sunandana Chandra, Caroline Robert, Jeffery S. Russell, Ann W. Silk, Jocelyn Booth, Suk Young Yoo, Frank Seebach, Israel Lowy, Matthew G. Fury, Danny Rischin
Dive into the research topics of 'A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6'. Together they form a unique fingerprint.